Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics), By Route of Administration (Oral, Intravenous, and Subcutaneous), and By Region - Trends, Analysis, and Forecast till 2029

Report Code: PMI441820 | Publish Date: March 2024 | No. of Pages: 165

Global Systemic Lupus Erythematosus Market Overview

Systemic Lupus Erythematosus Market accounted for USD 1.87 Billion in 2019 and is estimated to be USD 3.6 Billion by 2029 and is anticipated to register a CAGR of 7.0%

Systemic lupus erythematosus (SLE) is the chronic, autoimmune disorder which involves several organ-systems such as kidney, heart, blood, skin, joints, and lungs in most severe cases, brain. In this disease, the human immune system converts hyperactive and attacks the healthy, normal tissues of the body. SLE can often result in symptoms such as malar rash, sub-acute cutaneous lesions, discoid lesions, arthritis, photosensitivity, oral ulcers, serositis, nephropathy, thrombocytopenia, haemolytic anemia, neurologic involvement, fever, thrombosis, Raynaud’s phenomenon, livedo reticularis, and myositis.

Global Systemic Lupus Erythematosus Market Drivers & Restraints

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the occurrence of this disease is higher in the African-American and Asian populations. Women from the Asian, Afro-Caribbean and Hispanic descent are primarily affected by this disease. Over the past few decades, the SLE drugs market has observed a paradigm shift from generic and off label drugs to advanced innovator drugs with improved delivery options. Previously, the market was fortified with multiple drugs administered through conventional routes such as oral, intravenous and topical formulations. Nevertheless, the recent launch of a subcutaneous formulation of existing drug namely, Benlysta has resulted in the unmet requirement for the efficient and better innovator drugs with a convenient mode of delivery. Moreover, the systemic lupus erythematosus market would grow prominently over the forecast period owing due to factors such as rising ageing population, growing incidences of SLE, and increasing R&D investment on SLE drugs.

Conversely, factors hampering the target market growth are growing drugs prices and the presence of a stringent regulatory environment.

Global Systemic Lupus Erythematosus Market Segmentations & Regional Insights

The systemic lupus erythematosus market is segmented based on the drug classes, route of administration, and region.

On the basis of the drug classes, the systemic lupus erythematosus market is segmented into NSAIDs, corticosteroids, antimalarials, immunosuppressants, and biologics. Based on the route of administration, the target market is classified into oral, intravenous, and subcutaneous.

Regional Insights:

In the region, the systemic lupus erythematosus market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the market in 2019, with the U.S. at the leading position. The region is expected to maintain its dominance over the forecast period. Higher prevalence of SLE along with coverage for speciality drugs and improved healthcare infrastructure is driving to the growth of the regional market. Europe holds a second-highest regional market position in 2019, owing to five major European Union countries (Germany, U.K., Italy, Spain, and France) were the first to approve Benlysta as an add-on therapy for the treatment of active SLE. Moreover, due to improved coverage policies, there is greater adoption of belimumab since it is present in both formulations. Asia Pacific, Latin America, and Middle East & Africa remains behind due to low prominence in the market. Low revenue generation in these regions can be recognized due to the several factors, including low rheumatologist to population ratio, which prevents treatment and diagnosis at an early stage.

Attribute

Details

The base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Billion & CAGR from 2020 – 2029

Market Segmentation

By Drug Classes - NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics

By Route of Administration – Oral, Intravenous, and Subcutaneous

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2029.  For the purpose of this study, has segmented the systemic lupus erythematosus market report based on drug classes, route of administration, and region.

Systemic Lupus Erythematosus Market, By Drug Classes:

  • NSAIDs
  • Corticosteroids
  • Antimalarials
  • Immunosuppressants
  • Biologics

Systemic Lupus Erythematosus Market, By Route of Administration:

  • Oral
  • Intravenous
  • Subcutaneous

Global Systemic Lupus Erythematosus Market Competitive Landscape & Key Players

The key players operating in the systemic lupus erythematosus market include GlaxoSmithKline, Novartis, Roche, Bayer, Pfizer, Sanofi, F. Hoffmann-la Roche Ltd., Hadasit medical research services and development, Hansa medical ab, and Harbor biosciences. GlaxoSmithKline in collaboration with Roche is leading clinical trials with Benlysta and rituximab to regulate their combined efficacy in treating severe symptoms of SLE. Additionally, Novartis developed biosimilar rituximab at a low cost, which is utilized as an off label drug to drive the adoption of biological therapies in emerging regions.

Global Systemic Lupus Erythematosus Market Company Profile

  • GlaxoSmithKline
  • Novartis
  • Roche
  • Bayer
  • Pfizer
  • Sanofi
  • F. Hoffmann-la Roche Ltd.
  • Hadasit Medical Research Services and Development
  • Hansa Medical Lab
  • Harbor Biosciences

FAQs

The global systemic lupus erythematosus market is segmented based on drug classes, route of administration, and region.

The paradigm shift from generic and off label drugs to advanced innovator drugs with improved delivery options is likely to drive the growth of the global Systemic Lupus Erythematosus market over the forecast period.

North America leads the global market in 2019, with the U.S. at the leading position. The region is expected to maintain its dominance over the forecast period.

Multiple strategies such as new product launches, acquisitions, and joint ventures are adopted by the companies to enter the systemic lupus erythematosus market.